• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma

  1. M. Humbert1,
  2. W. Berger2,
  3. G. Rapatz3,
  4. F. Turk4

Article first published online: 18 MAR 2008

DOI: 10.1111/j.1398-9995.2008.01654.x

Issue

Allergy

Allergy

Volume 63, Issue 5, pages 592–596, May 2008

Additional Information

How to Cite

Humbert, M., Berger, W., Rapatz, G. and Turk, F. (2008), Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy, 63: 592–596. doi: 10.1111/j.1398-9995.2008.01654.x

Author Information

  1. 1

    Université Paris-Sud 11, Service de Pneumologie, Hôpital Antoine Béclère, Clamart, France

  2. 2

    Allergy and Asthma Associates, Mission Viejo, CA, USA

  3. 3

    Novartis Pharma AG, Basel, Switzerland

  4. 4

    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

*Prof. M. Humbert Service de Pneumologie et Réanimation Respiratoire Hôpital Antoine Béclère Assistance Publique Hôpitaux de Paris Université Paris-Sud 11 157, rue de la Porte de Trivaux 92140 Clamart France

Publication History

  1. Issue published online: 18 MAR 2008
  2. Article first published online: 18 MAR 2008
  3. Accepted for publication 20 December 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (217K)

References

  • 1
    Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999;54:301–307.
  • 2
    Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32–39.
  • 3
    Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O’Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287–291.
  • 4
    Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 2005;60(Suppl. II):P21.
  • 5
    Partridge MR, Van Der MT, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
  • 6
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–316.
    Direct Link:
  • 7
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004;59:709–717.
    Direct Link:
  • 8
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–190.
  • 9
    Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–261 [Erratum in: Eur Respir J 2001;18:739–740].
  • 10
    Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–638.
    Direct Link:
  • 11
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–308.
    Direct Link:
  • 12
    Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;10:1483–1492.
  • 13
    Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No 02-3659 (issued January 1995, revised 2002, 2005, 2006, 2007). National Institutes of Health/National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov. Available at http://www.ginastham.org; accessed 8 February 2008.
  • 14
    Humbert M, Holgate S, Boulet L-P, Bousquet J. Asthma control or severity: that is the question. Allergy 2007;62:95–101.
    Direct Link:
  • 15
    Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2006. Available at http://www.ginasthma.org; accessed 8 February 2008.
View Full Article (HTML) Get PDF (217K)